DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Summary for Patent: 8,637,451
|Title:||Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis|
|Abstract:||A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps.|
|Inventor(s):||Shailubhai; Kunwar (Audubon, PA), Nikiforovich; Gregory (St. Louis, MO), Jacob; Gary S. (New York, NY)|
|Assignee:||Synergy Pharmaceuticals Inc. (New York, NY)|
1. A method for stimulating water transport in the gastrointestinal tract in a patient comprising administering to said patient a guanylate cyclase receptor agonist peptide
consisting of SEQ ID NO:20, wherein said peptide is administered in an amount sufficient to induce cGMP production in a gastrointestinal epithelial cell and wherein said peptide is (4,12; 7,15) bicycle.
2. The method of claim 1, further comprising administering to said patient an effective dose of an inhibitor of cGMP-dependent phosphodiesterase either concurrently or sequentially with said guanylate cyclase receptor agonist peptide, wherein said inhibitor of cGMP-dependent phosphodiesterase is selected from the group consisting of sulindac sulfone, zaprinast, and motapizone.
3. The method of claim 1, wherein said peptide is formulated as a powder.
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.